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Extended passaging increases the efficiency of
neural differentiation from induced pluripotent
stem cells
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Abstract
Background: The use of induced pluripotent stem cells (iPSCs) for the functional replacement of damaged
neurons and in vitro disease modeling is of great clinical relevance. Unfortunately, the capacity of iPSC lines to
differentiate into neurons is highly variable, prompting the need for a reliable means of assessing the
differentiation capacity of newly derived iPSC cell lines. Extended passaging is emerging as a method of ensuring
faithful reprogramming. We adapted an established and efficient embryonic stem cell (ESC) neural induction
protocol to test whether iPSCs (1) have the competence to give rise to functional neurons with similar efficiency as
ESCs and (2) whether the extent of neural differentiation could be altered or enhanced by increased passaging.
Results: Our gene expression and morphological analyses revealed that neural conversion was temporally delayed
in iPSC lines and some iPSC lines did not properly form embryoid bodies during the first stage of differentiation.
Notably, these deficits were corrected by continual passaging in an iPSC clone. iPSCs with greater than 20 passages
(late-passage iPSCs) expressed higher expression levels of pluripotency markers and formed larger embryoid bodies
than iPSCs with fewer than 10 passages (early-passage iPSCs). Moreover, late-passage iPSCs started to express
neural marker genes sooner than early-passage iPSCs after the initiation of neural induction. Furthermore, late-
passage iPSC-derived neurons exhibited notably greater excitability and larger voltage-gated currents than early-
passage iPSC-derived neurons, although these cells were morphologically indistinguishable.
Conclusions: These findings strongly suggest that the efficiency neuronal conversion depends on the complete
reprogramming of iPSCs via extensive passaging.
Background
Induced pluripotent stem cells (iPSCs) are somatic cells
that have been epigenetically reprogrammed to a pluripo-
tent state using the ectopic expression of defined factors
(Oct3/4, Sox2, Klf4, c-myc, Nanog or Lin28) or small
molecule treatments [1-5]. Like embryonic stem cells
(ESCs), iPSCs have the ability to differentiate into all
three germ layers and thus, represent a viable option for
autologous cell replacement therapies. A number of
groups have investigated the potential of iPSCs for gener-
ating in vitro models of neurodegenerative maladies, such
as, Parkinson’s disease, retinal degeneration, amyotrophic
lateral sclerosis and Rett Syndrome [6-14]. Although
these studies are encouraging, little is currently known
about the molecular underpinnings of reprogramming
and the faithfulness with which iPSCs can recapitulate
neuronal differentiation.
Although iPSCs of both mouse and human origins
appear morphologically indistinguishable from ESCs,
several reports have emerged showing variations at the
transcriptomic and epigenomic levels [15-22]. In con-
trast, studies by Guenther et al. [23] and Neumann and
Cooper [24], have shown convincingly that the discrepan-
cies between iPSCs and ESCs are not significantly differ-
ent from variations between ESC lines with divergent
genetic backgrounds [23]. Moreover, laboratory-specific
factors such as culture conditions and reprogramming
methods may be an underlying cause of these observed
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differences [24]. Variations in teratoma forming ability,
hematopoiesis and neuronal differentiation have been
observed among mouse and human iPSC lines [25].
Recently, Polo et al. [26], Kim et al. [27] and Marchetto
et al. [28], observed that many early-passage mouse iPSC
lines maintain a persistent epigenetic signature of the tis-
sue type of origin. Interestingly, when directed to differ-
entiate to hematopoietic or osteogenic cell types, these
early-passage cells were biased toward their original cell
state, thus leading to low differentiation efficiency
[26,27]. At later passages, the iPSCs differentiated more
efficiently, which led the researchers to conclude that a
period of prolonged cellular proliferation may be a neces-
sary component of the reprogramming process. In light
of these findings, it has become clear that newly derived
iPSC lines should be thoroughly characterized based on
their expression of endogenous pluripotency genes, mor-
phology and differentiation capacity. However, informa-
tion is lacking whether extensive passaging has effects on
the competence of iPSCs to give rise efficiently to a neu-
ronal lineage.
The goal of this study was to assess the effects of passa-
ging on genetic stability in iPSCs and their efficiency in
giving rise to functional neurons. We also wished to
compare the neural differentiation potential of iPSCs
with that of ESCs, by performing quantitative evaluation
of temporal expression patterns of a battery of genes
expressed sequentially during neural development. Due
to the reported similarities between iPSC and ESCs, we
hypothesized that both cells undergo similar transitions
in the expression of key markers of neural differentiation.
We found that iPSC lines we generated had variable
competence to generate neural cells. We speculated that
these discrepancies could stem from the inherent hetero-
geneity of iPSC cultures prior to differentiation or a resi-
dual epigenetic signature from the tissue of origin
[26,27]. We found that, after continual passaging, an
iPSC line with a low efficiency of neural conversion
could recapitulate the gene expression patterns seen in
ESCs undergoing neural differentiation. These findings
highlight the importance of extensive cellular turnover
for establishing a fully reprogrammed state in iPSCs prior
to directed neural differentiation.
Results
Newly derived mouse iPSCs show variable neural
inductive ability at early-passages
We used 4 newly established mouse iPSC lines (denoted
as GG3.1/3 and miPS-20/25) and an established ESC line
derived from the inner cell mass of an R1 mouse embryo
(Additional file 1, Table S1) [29]. Three of the iPSC lines
were generated via retroviral transduction of mouse
embryonic fibroblasts with mouse Oct4, Sox2, Klf4
(miPS-20) and Nanog (miPS-25), whereas the GG3 clones
were transduced with human Oct4, Sox2 and Klf4. Nota-
bly, the reprogramming factor c-myc was omitted to
minimize the number of transgenes. The miPS-20/25
lines were generated using fibroblasts from transgenic
mice carrying a green florescent protein (GFP) gene dri-
ven by the Oct4 promoter; therefore, pluripotency and
differentiation could be monitored by the expression of
GFP (Figure 1B and Additional file 1, Fig. S1A) [30].
iPSCs and ESCs were maintained and subjected to a 2-
step neural induction protocol (Figure 1A) as previously
described [29]. All cell lines maintained a stereotypical
ESC morphology (e.g. enlarged nucleus with prominent
nucleoli and rounded cell clusters) in the presence of
Leukemia inhibitory factor (LIF) and fetal bovine serum
(Figure 1 and Additional file 1, Fig. S1). After adaptation
to feeder-free conditions iPSC cultures displayed sponta-
neous differentiation at the edges of most cell clusters
(Figure 1B-D and Additional file 1, Fig. S1). By contrast,
spontaneous differentiation in ESC cultures was
undetectable.
Pluripotent cells located in the center of these clusters
were revealed by alkaline phosphatase staining (Addi-
tional file 1, Fig. S2A), which was consistent with GFP
expression in miPS-20/25 (Figure 1B and Additional file
1, Fig. S1A). Upon dissociation and placement in serum-
free cellular suspension, all cell lines formed embryoid
bodies (EB), although the abundance of EBs varied
greatly in iPSC cultures (data not shown). When plated
and treated with neural induction medium, both ESC
and iPSCs displayed characteristic neuronal epithelial
morphology within 3 days (i.e. neural tube-like rosettes,
Figure 1 and Additional file 1, Fig. S1; Ni3). Neurite-like
processes extended from the cell clusters as early as 3
days after the start of neural induction (Figure 1B-D and
Additional file 1, Fig. S1). By day 7, neuron-like cells with
characteristic bipolar, multipolar and pyramidal
morphologies were observed in both ESC and iPSC cul-
tures (Figure 1B-D and Additional file 1, Fig. S1; Ni7).
The prevalence of EBs with at least some non-neuronal
morphologies was greater than 90% in all early-passage
iPSC cultures (n = 3). Specifically, rhythmically beating
cells with morphology resembling cardiomyocytes were
observed in approximately 10% of plated iPSC EBs and
multi-lineage cells were ubiquitous (Additional file 1, Fig.
S1C-E, n = 3).
Originally, we had concerns that transgene re-expres-
sion may be a confounding factor during the differentia-
tion process due to previous reports of this phenomenon
in iPSCs derived using retroviruses [3,4]. However, analy-
sis of endogenous transcripts for the reprogramming
factors, Oct4, Sox2 and Klf4, discounted transgene
expression in the GG3.1 line (Additional file 1, Fig. S2B).
The overall quality of this cell line was further ensured
by expression analyses of genes in the Dlk1-Dio3 locus
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Figure 1 iPSC lines subjected to neural induction (Ni) produce populations of neurons with similar morphology to ESC-derived
neurons. (A) Ni proceeds in three stages: (1) expansion of undifferentiated cells, (2) formation of embryoid bodies (EB) in a floating serum-free
culture and (3) neuronal differentiation on poly-d-lysine/laminin coated plates in the presence of N2-supplement and brain derived neurotrophic
factor (BDNF). (B, C) Representative micrographs for the miPS-25 (B), GG3.1 (C) and wild-type (WT) ESC lines at critical time points of neural
induction: Undifferentiated, EB day 5 and Ni days 3 and 7. Bars represent 100 μm.
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on chromosome 12 (Additional file 1, Fig. S2C and D).
Recent reports concluded that repression of this locus,
specifically the genes Gtl2 and Rian, is a defining feature
of poor quality mouse iPSCs that lack the ability to gen-
erate “all-iPSC mice” via tetraploid complementation
[31,32]. We analyzed the expression level of Gtl2 and
Rian in the GG3.1 line and found no difference in their
expression levels when compared to ESCs (Additional file
1, Fig. S2C and D). Moreover, no significant difference in
expression levels of Gtl2 and Rian was observed between
early- and late-passage iPSCs (Data not shown). Consid-
ering the final differentiation performance of the GG3.1
line (i.e. post-extended passaging), this method of iPSC
quality assessment should prove useful in future experi-
ments where new iPSCs are derived.
To better characterize cellular phenotype, we per-
formed immunocytochemistry on GG3.1 cells at neural
induction day 7. Thirty to forty percent (n = 3) of cells
stained positive for the early neural marker HuC/D, as
well as, the mature neural markers Synaptophysin (Syn),
ßIII-tubulin (TuJ1), microtubule associated protein 2
(MAP2) and neural nuclei protein (NeuN). As shown in
previous studies, a subset of cells expressed brain-speci-
fic homeobox/POU domain protein 3A (Brn3a), indicat-
ing the presence of sensory-like neurons (Figure 2A-D).
The majority of these cells were also positive for neuro-
filament and calretinin, consistent with our previous
analysis of ESC-derived neurons (Additional file 1, Fig.
S3D-F) [29]. Furthermore, we found that Map2, TuJ1,
NeuN and neurofilament expression persisted beyond
day 15 in iPSC cultures (data not shown). The presence
of Syn+ puncta and growth cones was indicative of
maturing neurons (Figure 2D). This staining profile is
consistent with the forebrain-like neurons observed in
our and others’ previous ESC analysis (See Additional
file 1, Fig. S3A-F for further characterization) [29,33].
From this point on, the GG3.1 and miPS-25 lines were
chosen for further analysis based on their disparate
methods of generation and ability to form spherical EBs
with similar abundance (~0.7-1 × 103/mL, n = 3) as
ESCs.
Extended passaging enhances pluripotent gene
expression in an undifferentiated state and increases the
rate/efficiency of neuronal conversion
Although iPSCs exhibit neural phenotypes similar to
ESCs at early-passages, we postulated that the observed
morphological and differentiation inconsistencies were a
result of either incomplete reprogramming or the hetero-
geneity of our iPSC cultures. Recent literature suggests
that a prolonged period of proliferation and self-renewal
may be necessary to stabilize iPSCs in a pluripotent state
[17,26]. Accordingly, we passaged iPSCs at least 10 times
prior to repetition of neural induction [26]. At 20-30
passages, spontaneous differentiation was undetectable in
both GG3.1 and miPS-25 cell lines, whereas GFP expres-
sion was uniform in the miPS-25 line (Figure 3A). Inter-
estingly, we observed a significant increase in the
diameter of EBs (~90-120 μm up to ~160-190 μm, n = 3)
derived from late-passage GG3.1 cells, which was equiva-
lent to the EB size seen in ESC cultures (Figure 3B).
Furthermore, relative to early-passage iPSCs, most cells
in late-passage GG3.1 cultures expressed Sox2, with few
observable differentiated Sox2- cells (Figure 4A and 4B).
Real-time qRT-PCR revealed that expression levels of the
pluripotency markers Oct4, Sox2, Rex1 and Nanog in
late-passage cultures were significantly higher than those
in early-passage iPSCs and were equivalent to expression
levels in ESCs (Figure 4D). Notably, Nanog expression in
late-passage cells remained significantly lower than in
ESCs, but there was an upward trend (Figure 4D).
To assess the transcriptional changes occurring in
iPSCs over the course of neural differentiation, we car-
ried out additional qRT-PCR using cDNA generated
from undifferentiated cells, cells at EB day 5, and neural
induction days 3 (Ni3), and 7 (Ni7). To clearly delineate
events of gene up- and down-regulation, we evaluated
the expression of immature- and mature-neuronal mar-
kers. Expression of pluripotency markers (Rex1, Oct4 and
Klf4) in iPSCs declined promptly during the EB stage and
subsequent differentiation (Additional file 1, Figs. S2A
and S3B). The immature-neural markers, Neurogenin1
(Ngn1), Musashi1 (Msi1), Sox1 and HuC/D are all transi-
ently expressed during in vivo neural development and
have been detected in our cultures previously [29,34]. As
expected, the mRNA levels of these genes in ESC cul-
tures elevated during early differentiation (Ni3), but
declined as neural induction proceeded (Ni7) (Figure
5A). By contrast, the induction of immature-neural mar-
ker genes was delayed in early-passage iPSCs (Figure 5A).
However, after 20-30 passages, temporal expression pat-
terns and levels of immature-neural markers were not
significantly different from ESCs (Figure 5A). We next
evaluated the expression of mature neural markers, neu-
ron specific enolase (NSE), Syn (Figure 5A), Calretinin
and TrkB (Additional file 1, Fig. S2B). We found consis-
tently that expression of these genes is induced by Ni3,
but increases dramatically by Ni7 in ESC cultures (Figure
5A). This pattern of expression was seen in early-passage
iPSCs, but was not as robust. As with the other markers,
late-passage iPSC-derived cultures exhibited significantly
higher levels of NSE and Syn expression than early-pas-
sage iPSCs at Ni7 (Figure 5A).
To better quantify the efficiency of neural differentia-
tion, we performed flow cytometry analysis for the
neural lineage marker CD24 [35-37]. Our data revealed
a lower percentage of CD24+ cells in early-passage
iPSC-derived cultures (~30%) compared to ESC-derived
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Figure 2 Neurons derived from GG3.1 iPSCs exhibit characteristic neuronal morphologies and are immuno-positive for several neural
markers. (A-C) Representative images of Ni day 7 cells, fixed and stained for (A) HuC/D and Synaptophysin (Syn), (B) neural nuclei (NeuN) and
Map2, or (C) Brn3a and Map2. Nuclei are stained with DAPI. (D) TuJ1 and Synaptophysin staining reveals the presence of growth cones (arrows)
and presumptive synaptic boutons (star) in late-passage GG3.1 cultures on Ni day 7, indicating functional maturity. Bar indicates 50 μm.
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Figure 3 The effects of continual passaging on cellular morphology, colony shape and EB formation. (A) > 95% of colonies displayed
spontaneous differentiation and loss of GFP expression in peripherally located cells of low-passage GG3.1 and miPS-25 cell clusters. Serial
passaging results in morphological stability and uniform GFP expression in > 85% of cell colonies in miPS-25 cultures. (B) EB diameter increased
after multiple passages (iPSC LP represents cells at P20-30) compared to early-passage cultures (iPSC EP represents cells at P7-9). ESC-derived EB
diameter also differs significantly from EP-derived EB (n = 3 for each group). Scale bars indicate 100 μm. Values are mean ± SD. *P < 0.01.
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cultures (~85.5%), which was in accordance with our
immunocytochemistry observations (Figure 5B). This
percentage increased to approximately 50% in early-pas-
sage iPSC neural induction day 15 cultures (data not
shown). Consistent with the PCR analysis, the late-
passage iPSCs at neural induction day 7 contained a
comparable percentage of CD24+ cells when compared
to ESCs (~83%, Figure 5B). Together, these results
showed that extended passaging enhances iPSC homo-
geneity and similarity to ESCs in our culture system.
Figure 4 Late-passage GG3.1 cells are more homogenously undifferentiated and have higher levels of pluripotency factor expression.
(A) Comparison of Sox2 stained cells in (A) EP, (B) LP and (C) ESC cultures. LP and ESCs form tight clusters of uniformly Sox2+ cells. Under the
same conditions, EP cells readily generate Sox2- cells as indicated by DAPI. (D) Real-time qRT-PCR reveals that mRNA expression for several
pluripotency factor genes is elevated towards ESC levels in LP GG3.1 cells. Nanog expression remains significantly lower. Values are mean ± SD
for 2-3 independent samples. Bars indicate 100 μm. *P < 0.05, **P < 0.001.
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iPSC derived neurons exhibit an improved functional
profile after extended passaging
To evaluate the functional status of iPSC-derived neu-
rons, we performed whole cell patch clamp experiments
between days 7-14 of neural induction (Figure 6). For
consistent analysis, we chose cells with a distinct bipolar
or multipolar morphology (Figure 6A). The average rest-
ing membrane potentials were similar between early and
late-passage iPSCs at ~55 mV, which was more depolar-
ized than those recorded in ESCs (Figure 6B). Using a
current step protocol, ~90% of patched ESC-derived neu-
rons elicited repeated action potentials and robust inward
and outward currents (Figure 6C). By contrast, early-
passage iPSC-derived neurons, although morphologically
similar to ESC-derived cells, produced only solitary or
paired action potentials with comparatively weak inward
and outward currents (Figure 6C). Action potentials were
recorded from only ~23% of cells. Hyperpolarizing the
cells (to ~-70 mV) typically did not substantially enhance
the ability of early-passage iPSC-derived neurons to gen-
erate repetitive action potentials. Moreover, these cells
displayed poor membrane integrity, as indicated by low
input resistances that tended to get even lower fairly
rapidly, which made recording difficult. Late-passage
iPSC-derived neurons were capable of producing action
potentials of similar amplitude and frequency as
Figure 5 The temporal pattern of proneural gene expression is equivalent in late-passage GG3.1 iPSCs and ESCs, but delayed or
suppressed in early-passage cells. (A) The relative mRNA expression of 4 early markers of neural commitment, Ngn1, Msi1, HuC/D and Sox1,
and 2 late markers, NSE and Syn, were quantified for undifferentiated, EB and Ni days 3 and 7 cultures. LP cultures showed a significant increase
and temporal shift in the expression of most markers, in congruence with ESC expression patterns. (B) The percentage of neural lineage cells in
undifferentiated and Ni day 7 EP, LP and ESC cultures as indicated by CD24 cell surface expression. Histograms are representative results of 3
separate experiments are shown. Values are mean ± SD for 2-3 independent samples. *P < 0.05.
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ESC-derived neurons. Robust action potentials were
recorded from ~58% of cells (Figure 6C). Accordingly,
the inward and outward currents (most likely sodium
and potassium currents, respectively, although this was
not empirically determined) were equivalent with those
detected in ESC neurons (Figure 6C).
Discussion
To our knowledge, this is the first study to specifically
compare the neural differentiation capacity between
early- and late-passage murine iPSCs. Of our four iPSC
lines, three (GG3.1/3 and miPS-25) generated neuronal
populations greater than 30% (n = 3 per line) of the
total cell populations in early-passage culture when we
applied an ESC-based neuronal induction protocol. Our
group and others have previously shown that this proto-
col yields neuronal population of greater than 80% pur-
ity using murine ESCs [29,33]. Quantitative gene
expression analysis revealed a similar, but temporally
delayed pattern of neural lineage gene expression
between ESCs and one iPSC line (GG3.1). We found
that serial passaging improved the stability and mainte-
nance of two newly derived iPSC lines in an undifferen-
tiated state (Figure 3). Moreover, upon neural induction,
late-passage iPSCs and ESCs undergo nearly identical
temporal changes in gene expression (Figures 4 and 5).
These results strongly suggest that sufficient cellular
divisions are necessary to generated stable iPSCs clones
Figure 6 Electrophysiological assessment of GG3.1 iPSC-derived neurons. (A) Micrograph showing a representative neuronal cell that was
targeted for recording. (B) Average resting membrane potentials for one set of experiments shows no discernable difference between EP and
LP neurons. (C) Representative traces for whole cell-patch clamp recordings in EP, LP and WT ESCs. Action potentials were elicited with 500 ms
long current injections of 2-340 pA. Current recordings were generated by stepping up membrane potential from -90 mV to +60 mV in 10 mV
increments.
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that can achieve directed differentiation efficiencies
comparable to ESCs.
The increase in expression of pluripotency factors in
late-passage GG3.1 cells (Figure 4B) seems to agree with
previous reports showing that differential gene expres-
sion between ESCs and iPSCs diminishes after passaging
[16,17]. Since the RNAs for our analyses were extracted
from whole cell populations, we must be careful in draw-
ing conclusions about the individual cells within iPSC
populations. The qRT-PCR data in Figure 4B is more an
indication of the homogeneity of undifferentiated cul-
tures, than a direct measure of pluripotency. For instance,
the mRNA from early-passage cultures may be diluted by
the mRNA of spontaneously differentiated cells, which
would lower the measured relative expression of genes
uniquely expressed in undifferentiated cells. Thusly,
these data suggest that late-passage GG3.1 cultures con-
tain a pluripotent population of cells roughly as homoge-
neous as our ESC cultures. Alternatively, we can
conclude that the pluripotent state of these iPSC lines is
more stable at later passages. Likewise, our analyses of
neural markers in Figure 5 demonstrates the compara-
tively equivalent percentage of cells expressing these
genes in late-passage GG3.1 and ESC cultures at each
time point. These similarities in gene expression are par-
ticularly noteworthy when one considers that GG3.1
iPSCs and ESCs were derived from mice with disparate
genetic backgrounds (i.e. B6-CD1 and R1, respectively).
Our results also point to functional differences
between early-passage and late-passage iPSC-derived
neurons. However, it is important to note that the
results in Figure 6 are not entirely comprehensive in
their assessment of each neural induction culture. For
instance, we did not label a specific subtype of neurons
for analysis (e.g. glutamatergic or GABAergic neurons);
thus, the neurons analyzed may have represented multi-
ple phenotypes despite having a similar morphology. In
future studies, the use of subtype-specific fluorescent
reporters may allow for more precise assessment of a
particular population of stem cell-derived neurons.
Regardless of these technical limitation, the generation
of repeated action potentials with corresponding Na+/K+
currents was used as a general criterion for excitatory
functional neurons. In early-passage cultures, we were
unable to record repeated action potentials even after 14
days of differentiation. This indicates that neurons
developing in early-passage cultures may be functionally
defective. We speculate that the extreme heterogeneity
of early-passage neural cultures may create an environ-
ment that is not conducive to functional maturation.
A growing body of work has demonstrated that iPSCs
can give rise to a wide array of neural subtypes using
protocols optimized for ESCs [9,12,38,39]. However, few
studies consider thoroughly the relative efficiency with
which differentiation occurs between ESCs and iPSCs.
Recently, Hu et al. published work showing that human
iPSC lines derived using disparate methods (i.e. integrat-
ing and non-integrating vectors) displayed variable effi-
ciencies when directed to differentiate into motor
neurons [38]. Remarkably, cell lines derived using non-
integrating episomal expression of the transgenes
appeared to be just as susceptible to variation in differ-
entiation potency as cells derived using retroviruses,
which suggests that variability is independent of deriva-
tion method. These findings are reminiscent of our
initial comparison of early-passage iPSCs and ESCs in
that differentiation potency failed to match that seen in
ESCs. It is noteworthy that the passage numbers of the
iPSC cell lines used by Hu et al. were not reported, so it
is possible that these observed differences could be atte-
nuated with sufficient cellular turnover. More recently,
Boulting et al. found that early- and late-passage human
iPSCs performed similarly during motor neuron differ-
entiation and functional analysis, despite karyotypic
abnormalities in some late-passage cell lines [39].
Since varying differentiation propensities among iPSC
lines appear to be independent of derivation methods,
the beneficial effect of repeated passaging may reveal an
underlying feature of cellular reprogramming in general.
It has been proposed that a residual signature or “mem-
ory” of the cell type of origin persists throughout the
reprogramming process in the form of hypo- or hyper-
methylated regions of the genome and/or aberrant gene
expression [26-28]. It is possible that hypermethylation of
neural gene promoter regions may have confounded
early-passage iPSC differentiation, although we did not
directly test this. Several new studies also report the gen-
eration of genetic mutations, deletions and copy number
variations during the reprogramming process [18,19,21].
Over successive cellular divisions, however, it appears
that epigenetic marks are progressively “erased” or, per-
haps, selected against. At the moment, the precise
mechanisms of this process are unclear, but the epige-
netic signature appears to be a phenomenon in both
mouse and human reprogrammed cells [17,26,27]. Of
note, Hussein and colleagues recently demonstrated that
early-passage human iPSC lines have a high prevalence of
genetic copy number variations. Surprisingly, the amount
of copy number variations declined rapidly over succes-
sive passages (i.e. > 15 passages) seemingly due to selec-
tive pressure on the aberrant cells [19]. It is feasible that
this phenomenon is reflected in our current observations.
For future investigations it will be necessary to examine
karyotypic stability and copy number variation over the
course of these experiments to determine if neural differ-
entiation is impacted by these factors.
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Conclusions
The work presented herein demonstrates that extended
passaging can lead to more stable iPSCs, which in turn
leads to more efficient neural differentiation. The utility of
this approach will certainly be elucidated by further stu-
dies examining the effect of passaging on chromosomal
stability in iPSCs. Importantly, the present results highlight
the need for improved screening methodologies to isolate
iPSC clones with the greatest potential for directed differ-
entiation. Future studies identifying methylation signatures
that define fully reprogrammed iPSCs will be helpful in
developing better assays to evaluate the progression of
reprogramming. Interestingly, some reports suggest that
neuronal conversion of recalcitrant iPSCs can be greatly
improved through treatment with chromatin-modifying
drugs or small molecules [27,39,40]. Undoubtedly, for the
eventual application of iPSCs in disease modeling or cell
replacement therapies, complete reprogramming will be
critical for unbiased analysis of disease progression and
safety.
Methods
ES and iPS cell culture, maintenance and analysis
iPSCs were generated by transducing mouse embryonic
fibroblasts (for genetic backgrounds see Supplementary
Table 1 in Additional File 1) with Moloney murine leu-
kemia viruses (MMLVs) carrying the coding regions of
mouse Oct4, Sox2, Klf4 and/or Nanog or human Oct4,
Sox2 and Klf4. R1 mouse embryonic stem cells and
iPSCs were maintained in culture as described pre-
viously (Figure 1A) [29]. Briefly, iPS and ES cells were
plated on gelatin-coated tissue culture plates and grown
in high-glucose Dulbecco’s Modified Eagle’s Medium
(DMEM) (Invitrogen) supplemented with 15% FBS (Invi-
trogen), 1.0 mM sodium pyruvate (Stemcell Technolo-
gies), 10 mM nonessential amino acids (Stemcell
Technologies), 0.01% penicillin streptomycin (Stemcell
Technologies), 2.0 mM L-glutamine (Stemcell Technolo-
gies), 1,000 units/ml leukemia inhibiting factor (Chemi-
con), and 0.055 mM 2-mercaptoethanol. Cells were
passaged by dissociation with 0.25% trypsin-EDTA every
2-3 days. Two days after passaging the health and phe-
notypic stability of the cells was assessed. Five to ten
representative DIC images were taken and then analyzed
on MetaMorph software. Dissociation of tightly packed
clones and/or the appearance of enlarged and flattened
cells were indicators of spontaneous differentiation.
Neural induction
After 6-8 (early) and 20-30 (late) passages, iPSC and late-
passage (30-40) ESCs were subjected to neural differen-
tiation according to a previously established procedure
for ESCs (Figure 1A) [29,33]. Cells were dissociated into
single cells using 0.25% trypsin-EDTA and resuspended
in differentiation medium containing Glasgow’s Mini-
mum Essential Medium (GMEM) (GIBCO/Invitrogen),
5% Knockout serum replacement (Invitrogen), 2.0 mM
L-glutamine, 1.0 mM sodium pyruvate, 0.1 mM nones-
sential amino acids, 0.01% penicillin streptomycin, and
0.1 mM 2-mercaptoethanol. Cells were plated on gelatin-
coated plates for 40 minutes to remove any residual fee-
der cells or partially differentiated cells. Cells were then
cultured in low adherence 100 mm bacterial plates for
5 days at a density of 5-10 × 104 (iPSC) or 5 × 104 (ESC)
cells per ml to allow embryoid body (EB) formation. Dif-
ferentiation medium was changed at day 3. On day 5,
EBs were plated en bloc on tissue culture plates or cham-
ber slides double-coated with poly-D-lysine (200 μg/ml)
and mouse laminin (10 μg/ml) at a density of 1-2 × 102
EBs per cm2 in fresh medium. Before plating, EB were
imaged to assess size and shape. At least 50 EBs were
analyzed using MetaMorph software to determine the
average EB diameter for each biological replicate.
Twenty-four-thirty-six hours post plating, the medium
was changed to neural induction medium contain-
ing GMEM, 1% N2, 2 mM glutamine, 1 mM sodium
pyruvate, 0.1 mM nonessential amino acids, 0.1 mM 2-
mercaptoethanol, 0.01% penicillin streptomycin and
10 ng/ml brain-derived neurotrophic factor (BDNF)
(PeproTech). Neural induction cultures were maintained
for 3, 7 or 15 days before cells were harvested for RNA
extraction, electrophysiological recordings, flow cytome-
try analysis, or fixation with 4% paraformaldehyde for
immunocytochemistry.
Quantitative RT-PCR
The relative expression levels of pluripotency markers
and early/mature neural markers were assessed by con-
ventional reverse transcriptase PCR (RT-PCR) or quanti-
tative real-time RT-PCR (qRT-PCR) using a previously
described procedure [41]. At various time points of cell
culture and neural induction (undifferentiated day 5-7,
EB day 5, and days 3, 7 and 15 of neural induction), total
RNA was isolated using the RNeasy Minikit (Qiagen) and
then treated with TURBO DNase (Ambion) to decrease
the likelihood of DNA contamination. Single-stranded
cDNA was synthesized using Omniscript reverse tran-
scriptase (Qiagen) and Oligo-dT primers. All amplicons
had standardized sizes of 100-110 bps. For non-quantita-
tive RT-PCR, the resultant cDNA was amplified with Pla-
tinum Taq DNA polymerase (Invitrogen) for 30 cycles.
For qRT-PCR, the cDNA samples were amplified on an
ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems) using the SYBR Green PCR Master
Mix (Applied Biosystems). For each PCR reaction, a mix-
ture containing cDNA template (5 ng), Master Mix, and
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forward and reverse primers (400 nM each) was treated
with uracil N-glycosylase at 50°C for 2 min before under-
going the following program: 1 cycles, 95°C, 10 min; 45
cycles, 95°C, 15 sec, 60°C, 1 min; 1 cycles, 95°C, 15 sec,
60°C, 15 sec, 95°C, 15 sec (for melting curve analysis);
72°C, hold. Melting curve analysis was performed to con-
firm the authenticity of the PCR products. For internal
control, PCR was run with cDNA samples using an L27
(ribosomal housekeeping gene) primer pair, whose PCR
product crosses an intron. To check the efficiency of pri-
mer pairs, a cDNA dilution series (1, 1/10, 1/100, and
1/1,000) was amplified. The mRNA level for each gene
was calculated relative to L27 mRNA expression. L27
expression was previously determined to be stable under
all experimental conditions [29]. Each data point repre-
sents the average of 7-10 replicates from 3-4 biological
samples. Statistical significance was determined using a
One-Way ANOVA followed by Scheffe’s post-hoc test.
Primer sequences used in this study are listed in Supple-
mentary Table 2 (Additional File 1).
Immunocytochemistry
Prior to differentiation and at days 3 and 7 of neural dif-
ferentiation, cultures were fixed with 4% paraformalde-
hyde for 30 min. Chamber slides were incubated in
blocking solution and then with a primary polyclonal and
a monoclonal antibody together. Primary antibodies used
in this study are listed in Supplementary Table 3 (Addi-
tional File 1). Immunoreactivity with monoclonal and
polyclonal antibodies was visualized by using an Alexa
Fluor 488 conjugated anti-mouse IgG and Alexa Fluor
568 conjugated anti-rabbit IgG, respectively. For visualiz-
ing cellular nuclei, the specimens were counterstained
with DAPI (Vector, VectaShield). Expression of certain
proteins was quantified using the imageJ (NIH) cell
counting plug-in. Regions with moderate cellular densi-
ties were chosen at random for 3 biological samples
unless stated otherwise.
Electrophysiology
Whole cell patch-clamp recordings were conducted as
described previously [29]. Briefly, experiments were per-
formed using an EPC-10 amplifier, and data was
acquired using the Pulse program (HEKA Electronics).
Putative bipolar neurons were selected for recording
based on morphology. The pipette solution contained:
140 mM KCl, 5 mM MgCl2, 5 mM EGTA, 2.5 mM
CaCl2, 4 mM ATP, 0.3 mM GTP, and 10 mM Hepes,
pH 7.3 (adjusted with KOH). The bathing solution con-
tained: 140 mM NaCl, 1 mM MgCl2, 5 mM KCl, 2 mM
CaCl2, 10 mM Hepes, and 10 mM glucose, pH 7.3
(adjusted with NaOH). Voltage-clamp and current-
clamp data was analyzed using the Pulsefit (HEKA
Electronics), Origin (OriginLab) and Microsoft Excel
software.
Flow cytometry
Cells were dissociated by a brief exposure to 0.25% tryp-
sin-EDTA. After blocking with serum, cells were incu-
bated with one of the following primary antibodies: anti-
CD24-phycoerythrin (PE), mouse immunoglobulin G
(IgG) isotype control or Alexa 568-conjugated anti-rab-
bit secondary antibody. Cell sorting and analysis were
performed with a FACSCalibur flow cytometry system
(BD Biosciences). Data analysis was performed using
FlowJo 8.6.6 software (Tree Star, Inc.).
Additional material
Additional File 1: Supplementary information. Supplementary Figures
1-3 and Tables 1-3. Supplementary Figure 1 - iPSCs (GG3.3 and miPS-
20) at various stages of neural differentiation. Representative
micrographs of miPS-20 (A) and GG3.3 (B) iPSCs prior to differentiation,
on day 5 of EB formation and on days 3 and 7 of neural induction. (C-E)
Examples of aberrant cell types with endodermal (C) and mesodermal
(D, E) morphologies that were prevalent during all early-passage iPSC Ni
experiments. Scale bars represent 100 μm. Supplementary Figure 2 -
The GG3.1 cell line is a competent iPSC line with no detectable
transgene re-expression during neural differentiation. (A) Alkaline
phosphatase staining of ESC and GG3.1 cells indicates pluripotent cells in
undifferentiated cultures and a gradual loss of pluripotency during the
EB stage. (B) Primers amplifying an untranslated region (UTR) of the Oct4,
Sox2 and Klf4 genes were compared to exon expression in
undifferentiated and neural induction days 3 and 7. All expression levels
were normalized to undifferentiated expression levels. The identical
pattern of expression indicates a lack of transgene re-expression. (C-D)
The GG3.1 cell line displays similar expression levels of the Dlk1-Dio3
locus genes Gtl2 and Rian, which is an indirect measure of complete
reprogramming. Equivalent expression of these genes was validated
using 2 different primer sets; one novel and one published by Stadtfeld
et al., 2010. Values are mean ± SD for 2-3 independent samples.
Supplementary Figure 3 - Expression of neural lineage and subtype
specific genes throughout Ni of early-passage GG3.1 iPSCs. (A-C)
Representative micrographs showing the presence and abundance of
HuC/D, Map2, neurofilament (NF) and Calretinin (Calr) positive cells at Ni
day 7. Scale bars represent 150 μm. (D) The pluripotency marker Rex1 is
downregulated during differentiation. (E) The anterior
neurodevelopmental gene Otx2 is expressed by day 5 of EB. The
neurotrophin receptor TrkB is expressed during the EB stage, but
expression is elevated by day 7 of Ni. Calretinin is expressed by Ni day 3.
(F) Markers of glutamatergic neurons, vesicular glutamate transporter 2
(VGLUT2) and the AMPA receptor subunit GluR2 are highly expressed by
days 7 and 15 of Ni. Likewise, the GABAergic neuronal marker, glutamic
acid decarboxylase 1 (GAD1) is unregulated by days 7 and 15. Values are
mean ± SD for 2-3 independent samples. Supplementary Table 1 -
Pluripotent stem cell lInes. Supplementary Table 2 - Primers.
Supplementary Table 3 - Antibodies.
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